Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52 Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of TEZSPIRE THOUSAND OAKS, Calif., Aug.
DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (" Jazz Pharmaceuticals ") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") by Jazz Investments I Limited,
European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart’s Norovirus vaccine program through at least 2036 across key European markets KEY HIGHLIGHTS: • European Patent Office (EPO) granted Vaxart a new patent: European Patent No. 3791859.
Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety results New poster will highlight the mechanistic characterization of azetukalner, including its potential additive effects when used with commonly prescribed ASMs VANCOUVER, BC and BOSTON, MA, Aug.
BOSTON --(BUSINESS WIRE)--Aug. 26, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investor Relations and Manisha Pai, Executive Director of Investor Relations, will
Advancing Earlier Diagnosis and Coordinated Care in ATTR-CM Anonymous (not verified) Wed, 26 Aug 2026 - 17:27
RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy In the Phase 3 RASolute 302 trial, RASONQUE reduced the risk of death by 60% and
JAMA Dermatology publication includes results from VALOR skin-specific secondary endpoints, with rapid and durable improvements seen for brepocitinib 30 mg compared to placebo across multiple dimensions of cutaneous dermatomyositis (DM), including measurements of disease activity, itch, and
Neonorm ® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogs Jaguar expects to make Neonorm Dog available through both Amazon and Chewy
If approved, REVTORPYK would be the first and only therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc.
NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak,
NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”)
Website Enables Families and Caregivers of Children with MPS IIIB to Learn About and Register Interest in the TA-ERT Expanded Access Program (EAP) and TrAnsform Confirmatory Study TA-ERT EAP and TrAnsform Confirmatory Study Both Expected to Initiate in the Fourth Quarter of 2026 SOUTH SAN
DUBLIN, Aug. 26, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (" Jazz Pharmaceuticals ") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal
First-of-its-kind study shows sustained Zepbound use in older adults with obesity lowers costs, reinforcing the potential value of the Medicare GLP-1 Bridge program Individuals treated with Zepbound had lower rates of hospital admissions and emergency department visits INDIANAPOLIS, Aug.
SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim. Opakalim, the lead candidate from Biohaven's Kv7 platform, is a
NEW HAVEN, Conn., Aug. 25, 2026 /PRNewswire/ -- Biohaven Ltd. and/or its wholly owned subsidiaries (" Biohaven ") (NYSE: BHVN) and Yale University ("Yale") today announced that the U.S. District Court for the District of Delaware has entered judgment in their favor in the trade secret
NOVATO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 45,984 restricted stock units of the
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code:
Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that Robin Kramer, Chief Financial Officer, and Adam Keeney, Head of Corporate Development, will participate in a fireside chat during the Wells Fargo 21st Annual Healthcare Conference. The webcast will be live on Wednesday, Sept 9,
SAN DIEGO --(BUSINESS WIRE)--Aug. 25, 2026-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that
Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50) SPY072 was well tolerated with rates of adverse events comparable to placebo
COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasia Society being held in Toronto, Canada, from August 26-29, 2026, will include an oral presentation
Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, providing a new treatment option in front-line GEA Second FDA approval for zanidatamab in less than two years further validates Zymeworks’
Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, establishing a new standard of care in front-line GEA Company to host investor webcast on Aug. 25 at 4:30 p.m. ET For U.S.
Human studies show that the TGF-β trap and IL-15 fusion used alone promotes expansion of progenitor CD8 + T cells and NK cells Company has incorporated the TGF-β/IL-15 moiety into the constructs of its second-generation fusion immunotherapeutics constructed with novel TRBC drug development platform
Media Release COPENHAGEN, Denmark; August 25, 2026 Genmab A/S (Nasdaq: GMAB) announced today that members of its E xecutive Committee will participat e in fireside chats at the following investor conferences in September 2026: Wells Fargo 21st Annual Healthcare Conference in Boston on September
REZOLVE-AD study met all primary and key secondary endpoints, including EASI -75, EASI -90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w First large, placebo-controlled trial to support T-reg modulation as a clinical mechanism for immunoregulation of chronic inflammatory disease
EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Rajiv Patni, M.D., as Chief Medical Officer. Dr.
ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across its late-stage pipeline of potential first-and best-in-class gene therapies, Mr.
RNS Number: 0041S PureTech Health PLC 25 August 2026 25 August 2026 PureTech Health plc PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress Presentations will highlight Celea's differentiated approach to
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and
— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to
Houston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, announced today that it has agreed to sell 12,945,916
All clinical trial sites identified and CRO retained Patient screening expected to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, Aug. 25, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its
25 August 2026 AstraZeneca prices €2.55 billion bond offering AstraZeneca PLC (the Company) announces that, on 24 August 2026, its wholly owned subsidiary AstraZeneca Finance LLC, successfully priced four tranches of Eurobonds totalling €2.55 billion (the Offering)....
DLL3-targeting Radio-DARPin MP0712 progressing in Phase 1/2a trial, now recruiting at dose level 2; initial data expected in 2026, efficacy data expected in 2027 CD70 selected as new radio target for the treatment of kidney cancer and other indications, with clinical program start anticipated in
Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open Topco common stock expected to commence trading on Nasdaq
– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy – – At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue, Cognition and